美國食品藥物管理局核准的92個癌症新藥讓病人多活多久?答案大吃一驚~
【30秒重點】
- 癌症新藥上市不等於能多活很久,可以問醫師:這個藥能讓我多活多久?
- JAMA研究:2000到2016年FDA核准92個癌症新藥,共100個適應症、127個臨床試驗。
- 只有約51.2%是隨機試驗,74.8%是沒有盲性的開放性試驗。
- 這些藥物讓病人多活的中位數只有2.4個月。
2020/11/15
摘要
過去17年 (2000~2016) 通過美國食品藥物管理局的92個癌症新藥,127個臨床試驗,核准100個適應症。次分析發現,屬於隨機臨床試驗(RCT)佔約一半(65; 51.2%),95個(74.8%)試驗並未維持盲性 (blinding),屬於開放性試驗。
重點來了,試驗發現這些藥物能讓病人平均「多」活多久?絕對中位數(Median)增加多少?答案是:
2.4個月。
Results
Between 2000 and 2016, 92 novel cancer drugs were approved by the FDA for 100 indications based on data from 127 clinical trials. The 127 clinical trials included a median of 191 participants (interquartile range [IQR], 106-448 participants). Overall, 65 clinical trials (51.2%) were randomized, and 95 clinical trials (74.8%) were open label. Of 100 indications, 44 indications underwent accelerated approval, 42 indications were for hematological cancers, and 58 indications were for solid tumors. Novel drugs had mean hazard ratios of 0.77 (95% CI, 0.73-0.81; I2 = 46%) for overall survival and 0.52 (95% CI, 0.47-0.57; I2 = 88%) for progression-free survival. The median tumor response, expressed as relative risk, was 2.37 (95% CI, 2.00-2.80; I2 = 91%). The median absolute survival benefit was 2.40 months (IQR, 1.25-3.89 months).
留言
張貼留言